On 8 April 2024, Samsung Bioepis released its fifth US Biosimilar Market Report. The quarterly report details average sales price information for US launched biosimilars and market share and price trends.
The Q2 2024 Report notes that as of April 2024, the FDA has approved 48 biosimilars, with three of those (Alvotech’s/Teva’s Simlandi® (Humira®, adalimumab), Sandoz’s Jubbonti®/Wyost® (Prolia®/Xgeva®, denosumab) and Fresenius Kabi’s Tyenne® (Actemra®, tocilizumab) approved in the last quarter. 38 of the 48 approved biosimilars have launched in the US.
Samsung Bioepis reports that, on average, biosimilars in the US have gained 53% market share within 3 years post initial launch. As at Q4 2023, the adalimumab biosimilars share of the US adalimumab market was 4%, although this was up 2% compared with last quarter. The first biosimilar was launched in January 2023 (Amjevita™, Amgen) and multiple additional biosimilars entered the US market in July 2023.